Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
Conditions
Stage II Breast Cancer - Stage III Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
Capecitabine, Neoadjuvant therapy, Early Breast Cancer
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: fluorouracil Type: Drug
Name: capecitabine Type: Drug
Name: cyclophosphamide Type: Drug
Name: Epirubicin Type: Drug
Overall Status
Not yet recruiting
Summary
This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Females aged 18-70 with histologically proven, core-biopsied, Stage II-III invasive breast cancer

- No distant disease

Exclusion Criteria:

- Inadequate heart or liver or kidney function
Location
Breast Cancer Surgery Department of Guangxi Medical University Cancer Center
Nanning, Guangxi, China
Status: Not yet recruiting
Contact: Jianlun Liu, MD
Start Date
June 2014
Sponsors
Guangxi Medical University
Source
Guangxi Medical University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page